Adhesion G protein-coupled receptors (aGPCRs) are critical for a variety of biological and pathophysiological processes, including modulation of metabolic (Olaniru and Persaud, 2019) and immune responses (Lin et al., 2017) to regulatory roles in the central and peripheral nervous systems (Folts et al., 2019). In addition, several lines of evidence suggest key functions for aGPCRs in cancer where they may, for example, relay cellular signaling in response to surrounding mechanical cues (reviewed in Scholz, 2018).

Mechanosensory roles may prove to be a general feature of these receptors, in relation to the overall structure of aGPCRs and the mode of activation that was recently identified (Langenhan, 2019). In aGPCRs, a large extracellular domain, termed the N-terminal fragment (NTF), is linked to the transmembrane 7 domain (7TM), which is referred to as the C-terminal fragment (CTF) of the protein. The NTF and CTF fragments are linked by GPCR autoproteolysis-inducing (GAIN) domain containing an autocatalytic cleavage site (GPS) motif that is activated during receptor processing. Following proteolytic cleavage, the NTF and CTF remain associated via non-covalent interactions during trafficking to the cytoplasmic membrane (Araç et al., 2012). Groundbreaking work by Liebscher et al., 2014 and Stoveken et al., 2015 has shown that the CTF, in the absence of the NTF, possesses basal signaling activity and that the 15–27 most N-terminal amino acids of the CTF act as a tethered activating ligand, reminiscent of the activation mode of the thrombin receptor (Seeley et al., 2003). In light of these data, it is conceivable that interactions of the NTF with extracellular matrix (ECM) components, or with membrane components of neighboring cells, serve as an anchor for the receptor and that binding of an additional ligand, or generation of tension (e.g., shear stress, stiffness of the ECM), changes the structural conformation, thereby releasing or altering the conformation of the NTF, resulting in exposure of the tethered agonist and activation of the receptor.

Several studies have shown constitutive basal activity of CTF constructs and activation of full-length aGPCRs with exogenous synthetic peptides (which we refer to as GPCR-activating peptides [GAPs]) corresponding to their cognate tethered agonist sequence (Liebscher et al., 2014; Demberg et al., 2015; Müller et al., 2015; Stoveken et al., 2015; Wilde et al., 2016; Brown et al., 2017; reviewed in Bassilana et al., 2019). Specifically, release of the NTF concomitant to receptor activation has been shown for GPR56/ADGRG1 upon binding to the ECM laminin 111 and transglutaminase 2 (Luo et al., 2014) and for EMR2/ADGRE2 bound to the ECM dermatan sulfate and subjected to mechanical cues (vibration) (Boyden et al., 2016; Le et al., 2019; Naranjo et al., 2020). However, it is important to note that some adhesion GPCRs such as CELSR1/ADGRC1, GPR115/ADGRF4, and GPR111/ADGRF2 lack a consensus GPS site and do not show evidence of cleavage. Further, the biological functions of GPR114/ADGRG5 and LAT1 (LPHN1/ADGRL1) are independent of cleavage at the GPS site, suggesting that these receptors may be activated by other structural changes (Langenhan, 2019; Scholz et al., 2017; Beliu et al., 2021).

In order to gain insight into the mechanisms of receptor activation at the level of the TM domains, several studies analyzed activation motifs and conserved functional elements within the TMs from various GPCR classes (Peeters et al., 2016; Arimont et al., 2019). For example, Nazarko et al., 2018 performed a comprehensive mutagenesis screen of LPHN1/ADGRL1. For the tethered agonist peptide, a beta strand conformation was suggested followed by a turn element that may be key in receptor activation (detailed in Vizurraga et al., 2020). However, only recently a first study explored in greater detail the modalities of the tethered agonist-mediated activation for GPR64/ADGRG2 (Sun et al., 2021). This study highlighted the importance of two residues within extracellular loop (ECL)2 and the tryptophan (W) toggle switch in TM6, showing reduced binding of an optimized peptide upon mutation. These functional data were recently complemented by cryo-EM structures of several aGPCRs in the presence of their activating tethered peptide (Qu et al., 2022; Xiao et al., 2022; Ping et al., 2022; Barros-Álvarez et al., 2022).

In this study, we set out to investigate the molecular mechanisms of tethered agonist-induced activation of the aGPCR GPR116/ADGRF5. GPR116 is expressed in several tissues and cell types, including alveolar type II epithelial (AT2) cells in the lung. One of the primary roles of GPR116 is in the regulation of pulmonary surfactant as revealed by global knock-out of the gene in mice (Bridges et al., 2013; Yang et al., 2013; Fukuzawa et al., 2013; Niaudet et al., 2015). Cell-specific deletion of GPR116 in AT2 cells of adult mice, or deletion of the downstream signaling proteins GNAQ/GNA11, recapitulated the increased pulmonary surfactant phenotype observed in the global knock-out mouse model (Brown et al., 2017). With respect to putative ligands, GPR116 has been proposed to associate with surfactant protein D (SFTPD) via its NTF (Fukuzawa et al., 2013). However, evidence supporting a direct role for SFTPD in the activation of GPR116 is lacking. Additionally, FNDC4 has recently been shown to activate GPR116-mediated Gs signaling in adipocytes (Georgiadi et al., 2021). Whether FNDC4 modulates Gq-mediated signaling via GPR116 in pulmonary AT2 cells remains to be determined.

In order to evaluate the role of the GPS cleavage and the tethered agonist for in vivo activation and functionality of GPR116, we generated knock-in mice in which autocatalytic cleavage at the GPS site is abolished. This approach has been employed for other aGPCRs in Caenorhabditis elegans and in vitro systems, using mutations immediately upstream or downstream of the GPS cleavage site (Kishore et al., 2016; Prömel et al., 2012; Peeters et al., 2015). In addition, we generated synthetic peptides corresponding to the tethered ligand sequence and mutations within the extracellular loops (ECLs) of GPR116 to identify key amino acid residues involved in receptor activation. Finally, we developed a GPR116 homology model based on recently published cryo-EM structures of ADGRF1/GPR110 (Qu et al., 2022). Together, our findings provide additional insight into the molecular mechanisms underlying the activation of GPR116/ADGRF5.

While great strides have been made in delineating the mechanisms of activation of aGPCRs in vitro, the mode of activation of adhesion GPCRs in vivo, including GPR116, is not well understood. Through generation and characterization of a cleavage-deficient mutant, H991A, we show that cleavage at the GPS site is required for GPR116 activity and modulation of pulmonary surfactant levels in vivo. These studies validate a tethered agonist-mediated activation mode for GPR116 in alveolar type 2 epithelial cells and alveolar homoeostasis. This is, to our knowledge, the first in vivo demonstration of the key role of the GPS cleavage and the unmasking of a tethered agonist in a mammalian system.

The tethered agonist sequence of each aGPCR family member is highly conserved between species, which explains cross-activation among orthologs (Liebscher et al., 2014; Brown et al., 2017). In this study, we identified F995, L998, and M999 as key amino acids in the tethered agonist sequence required for GPR116 activation. These three amino acids are highly conserved in the ECDs of multiple aGPCR CTFs (Supplementary file 1) and have been highlighted for other receptors such as GPR126/ADGRG6, GPR133/ADGRD1, GPR110/ADGRF1, GPR56/ADGRG1 (Liebscher et al., 2014; Stoveken et al., 2015), suggesting that they play a critical structural role for activation in the aGPCR family. In this sense, these data may explain some of the promiscuous activities observed within and between aGPCR subfamilies (Demberg et al., 2017).

Other studies aimed at analyzing the critical residues comprising the tethered agonist are consistent with our identification of phenylalanine at position 3 (F995) as the most N-terminal residue playing a key role in aGPCR activation (GPR64/ADGRG2, Azimzadeh et al., 2019 and Sun et al., 2021; GPR126/ADGRG6, Liebscher et al., 2014; Lphn3/ADGRL3, Mathiasen et al., 2020). Similarly, amino acids at positions 6 and 7 (L998 and M999), albeit not strictly conserved as leucine and methionine residues in all aGPCR tethered ligands, are key for GPR116 activation. It is noteworthy that additional residues within the tethered agonist that were dispensable for GPR116 activity are critical for other aGPCRs, possibly explaining the specificity for activation exhibited by some receptors. For example, alanine substitution of the first amino acid within the tethered agonist (usually a threonine) can lead to a loss of activity (Liebscher et al., 2014) while substitution with a hydrophobic residue can increase the activity of the peptide (Sun et al., 2021). This is consistent with our observations with the GAP10-Pro1 peptide, further supporting the concept that position 1 can modulate the strength of molecular interactions between ligand and its binding domain during aGPCR activation.

With respect to the 7TM, our mutational analysis of the extracellular surface of GPR116 identified ECL2 and top of TM6/ECL3 as the structural components most involved in receptor activation. Mutation of key residues may prevent GPR116 from transitioning to an active state or may prevent interaction with the tethered agonist peptide. We identified Y1158, R1160, W1165, and L1166 in ECL2 and T1240 at the TM6/ECL3 interface to be the key residues involved in GPR116 activation. Interestingly, we noted that W1165 and L1166, which immediately follow the cysteine involved in the disulfide bridge linking the top of TM3 and ECL2, comprise a CWL triad that is key for receptor activation. The tryptophan residue is globally conserved in aGPCRs, and the leucine (or sometimes isoleucine) is frequently present in this position (Supplementary file 1). Residues within ECL2 have also been implicated in ligand binding and activation of classical GPCRs (Wheatley et al., 2012). In particular, the CW motif in the ECL2 is conserved in family B, suggesting commonalities in the activation mechanism between aGPCRs and family B GPCRs. In particular, the (C)WF in ECL2 is involved in CRF1 binding to CRF1R (Gkountelias et al., 2009). In PAR1, a (C)HD sequence is important for receptor activation by the peptide, further highlighting the relevance of the ECL2 amino acids following the disulfide bridge, not only for activation per se but also ligand binding (OBrien et al., 2001). Within the aGPCR family, Sun et al., 2021 and Gad et al., 2021 also identified the (C)WI triad in ECL2 and residues in TM6 as being involved in GPR64/ADGRG2 activation by the tethered agonistic peptide. The tyrosine at position 1158 is located six amino acids upstream of the CWL triad and it is conserved in most aGPCRs, except in the ADGRA and ADGRG subfamily members, and ADGRV1 (Supplementary file 1). It is noteworthy that the CWL cluster is also less strictly conserved in these ADGRs. It is possible that a tyrosine at a position further upstream in the ECL2 may functionally replace Y1158 in these receptors, depending on the flexibility of the ECL. With regard to position 1240, a role for ECL3 in aGPCR activation has already been suggested for disease-associated mutations of GPR56/ADGRG1 (Chiang et al., 2017; Kishore and Hall, 2017; Luo et al., 2014). The mutation L640R (corresponding to H1250 in GPR116) in ECL3 affects collagen 3-mediated activation of GPR56 signaling, likely by inducing a conformation that locks the receptor in an inactive state. While the mutational work presented here highlighted features in line with previously published studies on aGPCR activation, interpretation of the functional data is limited and addressing the role of the identified key amino acids in GPR116 activation was further investigated in a homology model.

Indeed, recently, nine cryo-EM structures of aGPCRs, not including GPR116, were published (Barros-Álvarez et al., 2022; Ping et al., 2022; Qu et al., 2022; Xiao et al., 2022). These structures highlight, among other aspects, that the stachel is indeed buried into the 7TM domain, consistent with our data, with a key role of hydrophobic amino acids in positions 3, 4, 5, 7 of the tethered agonist and that the ECL2 can also bend into the barrel with variations depending on the receptor. The agonist peptide is surrounded by ECL2 and TMs on one side, and ECL3 and TMs on the other side. These structures confirm the key role ECL2, and it will be interesting to compare aGPCR activation with that of GPR52, recently shown to involve residues within ECL2 (Lin et al., 2020). Although the tryptophan following the cysteine bridge is critical for receptor activation in all aGPCRs, additional essential residues appear distinct in the various studied receptors.

The homology model of human GPR116 confirms that amino acids in ECL2 are important for receptor activation, even if it is surprising that only three residues facing the extracellular side (two in ECL2, one in ECL3) are involved in interactions with the tethered peptide. Based on this model, we could address a role for amino acids identified as key for activation, with some residues being involved in interactions mediating the activation and others being involved in receptor or peptide conformation and stabilization. In particular, the C-terminal part of the peptide (S1000 to S1008) forms intramolecular interactions stabilizing the peptide and Y1158-L1166 in ECL2 may participate in receptor stabilization than activation.

Relative to receptor activation, we identified key residues conserved in the ADGR family such as the tryptophan following the ECL2 cysteine involved in the disulfide bridge or the methionine conserved in most family members at position 7 in the tethered peptide. The homology model also highlighted GPR116-specific residues and interactions, such as R1160 and P1001 conserved in ADGRFs. Further, the species comparison studies highlighted that the mouse sequence-specific amino acids T1254 and A1258 in TM7 strengthen receptor activation by the peptide. The GPR116 homology model shows that the corresponding amino acids in the human sequence, A1254 and V1258, do form contacts with F995 of the tethered agonist peptide. This supports the possibility that the mouse variants induce stronger activation by the peptide, for example, via H bonds by the threonine. Further, it supports our finding that exchanging F995 with proline generates a mouse-specific peptide that is active on a human GPR116 construct exhibiting the mouse sequence at these two positions. The details of such interactions, including the glycine to lysine exchange at position 1011, cannot be predicted using this human GPR116 model and will require further studies.

While the model of the GPR116 activation that we present here is in line with other studies of aGPCRs and highlights aspects of tethered agonist:ECL2 interactions, it does have some limitations. First, further studies using cross-linking and binding experiments will be required to define the contact points between the tethered peptide and ECL2. Second, the potential role of the NTF, how it is positioned relative to the CTF, and how it may affect tethered agonist structure is not known. Modeling the highly flexible loops remains challenging, although some studies focused on modeling of GPCR ECLs are underway (Wink et al., 2019; Liessmann et al., 2021). In particular, ECL2 is the largest ECL in GPR116, as in many other GPCRs, and the disulfide bridge within TM3 does not introduce sufficient constraints to provide a more defined model. Even with adequate representation of the amino acid stereochemistry, significant degrees of freedom remain for the ECL conformation. Third, our studies evaluate the interaction of the tethered agonist with ECL2 in a context devoid of the NTF. In a setting of peptide- or antibody-based activation without NTF removal, exemplified recently by Mitgau et al., 2022 for GPR126, these tethered agonist/ECL interactions may be different.

Finally, it will be interesting to investigate whether the proposed FNCD4-mediated activation of GPR116, via binding to the NTF and subsequent G protein-coupling, also involves the tethered peptide sequence or another mechanism to induce activating structural changes in the 7TM.

Based on this study, our working model postulates that following unveiling of the tethered agonist, residues within this sequence interact with amino acids located in ECL2, ECL3, and TM7 to induce conformational changes, resulting in productive Gq/G11 engagement and activation. While the endogenous ligand or the biological process(es) leading to displacement and/or conformational change of the non-covalently linked N-terminal domain and subsequent GPR116 activation in vivo remain unknown, our data advance the mechanistic understanding of GPR116 activation in the context of pulmonary surfactant homeostasis and may facilitate the development of novel receptor modulators that can be used to treat clinically relevant lung diseases.

Source data for the modeling is provided (coordinates of the model).

1. 1. Araç D
   2. Boucard AA
   3. Bolliger MF
   4. Nguyen J
   5. Soltis SM
   6. Südhof TC
   7. Brunger AT

   (2012) A novel evolutionarily conserved domain of cell-adhesion gpcrs mediates autoproteolysis

   The EMBO Journal 31:1364–1378.

   https://doi.org/10.1038/emboj.2012.26

   • PubMed
   • Google Scholar
2. 1. Arimont M
   2. van der Woude M
   3. Leurs R
   4. Vischer HF
   5. de Graaf C
   6. Nijmeijer S

   (2019) Identification of key structural motifs involved in 7 transmembrane signaling of adhesion gpcrs

   ACS Pharmacology & Translational Science 2:101–113.

   https://doi.org/10.1021/acsptsci.8b00051

   • Google Scholar
3. 1. Azimzadeh P
   2. Talamantez-Lyburn SC
   3. Chang KT
   4. Inoue A
   5. Balenga N

   (2019) Spatial regulation of GPR64/ADGRG2 signaling by β-arrestins and GPCR kinases

   Annals of the New York Academy of Sciences 1456:26–43.

   https://doi.org/10.1111/nyas.14227

   • PubMed
   • Google Scholar
4. 1. Barros-Álvarez X
   2. Nwokonko RM
   3. Vizurraga A
   4. Matzov D
   5. He F
   6. Papasergi-Scott MM
   7. Robertson MJ
   8. Panova O
   9. Yardeni EH
   10. Seven AB
   11. Kwarcinski FE
   12. Su H
   13. Peroto MC
   14. Meyerowitz JG
   15. Shalev-Benami M
   16. Tall GG
   17. Skiniotis G

   (2022) The tethered peptide activation mechanism of adhesion gpcrs

   Nature 604:757–762.

   https://doi.org/10.1038/s41586-022-04575-7

   • PubMed
   • Google Scholar
5. 1. Bassilana F
   2. Nash M
   3. Ludwig MG

   (2019) Adhesion G protein-coupled receptors: opportunities for drug discovery

   Nature Reviews. Drug Discovery 18:869–884.

   https://doi.org/10.1038/s41573-019-0039-y

   • PubMed
   • Google Scholar
6. 1. Beliu G
   2. Altrichter S
   3. Guixà-González R
   4. Hemberger M
   5. Brauer I
   6. Dahse AK
   7. Scholz N
   8. Wieduwild R
   9. Kuhlemann A
   10. Batebi H
   11. Seufert F
   12. Pérez-Hernández G
   13. Hildebrand PW
   14. Sauer M
   15. Langenhan T

   (2021) Tethered agonist exposure in intact adhesion/class B2 gpcrs through intrinsic structural flexibility of the GAIN domain

   Molecular Cell 81:905–921.

   https://doi.org/10.1016/j.molcel.2020.12.042

   • PubMed
   • Google Scholar
7. 1. Boyden SE
   2. Desai A
   3. Cruse G
   4. Young ML
   5. Bolan HC
   6. Scott LM
   7. Eisch AR
   8. Long RD
   9. Lee C-CR
   10. Satorius CL
   11. Pakstis AJ
   12. Olivera A
   13. Mullikin JC
   14. Chouery E
   15. Mégarbané A
   16. Medlej-Hashim M
   17. Kidd KK
   18. Kastner DL
   19. Metcalfe DD
   20. Komarow HD

   (2016) Vibratory urticaria associated with a missense variant in ADGRE2

   The New England Journal of Medicine 374:656–663.

   https://doi.org/10.1056/NEJMoa1500611

   • PubMed
   • Google Scholar
8. 1. Bridges JP
   2. Ludwig MG
   3. Mueller M
   4. Kinzel B
   5. Sato A
   6. Xu Y
   7. Whitsett JA
   8. Ikegami M

   (2013) Orphan G protein-coupled receptor GPR116 regulates pulmonary surfactant pool size

   American Journal of Respiratory Cell and Molecular Biology 49:348–357.

   https://doi.org/10.1165/rcmb.2012-0439OC

   • PubMed
   • Google Scholar
9. 1. Brown K
   2. Filuta A
   3. Ludwig MG
   4. Seuwen K
   5. Jaros J
   6. Vidal S
   7. Arora K
   8. Naren AP
   9. Kandasamy K
   10. Parthasarathi K
   11. Offermanns S
   12. Mason RJ
   13. Miller WE
   14. Whitsett JA
   15. Bridges JP

   (2017) Epithelial gpr116 regulates pulmonary alveolar homeostasis via gq/11 signaling

   JCI Insight 2:93700.

   https://doi.org/10.1172/jci.insight.93700

   • PubMed
   • Google Scholar
10. 1. Chen B
    2. Gilbert LA
    3. Cimini BA
    4. Schnitzbauer J
    5. Zhang W
    6. Li GW
    7. Park J
    8. Blackburn EH
    9. Weissman JS
    10. Qi LS
    11. Huang B

    (2013) Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/cas system

    Cell 155:1479–1491.

    https://doi.org/10.1016/j.cell.2013.12.001

    • PubMed
    • Google Scholar
11. 1. Chiang NY
    2. Peng YM
    3. Juang HH
    4. Chen TC
    5. Pan HL
    6. Chang GW
    7. Lin HH

    (2017) GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated gα_12/13/rhoa signaling

    The Journal of Investigative Dermatology 137:727–736.

    https://doi.org/10.1016/j.jid.2016.10.031

    • PubMed
    • Google Scholar
12. 1. Cvicek V
    2. Goddard WA
    3. Abrol R

    (2016) Structure-based sequence alignment of the transmembrane domains of all human gpcrs: phylogenetic, structural and functional implications

    PLOS Computational Biology 12:e1004805.

    https://doi.org/10.1371/journal.pcbi.1004805

    • PubMed
    • Google Scholar
13. 1. Demberg LM
    2. Rothemund S
    3. Schöneberg T
    4. Liebscher I

    (2015) Identification of the tethered peptide agonist of the adhesion G protein-coupled receptor GPR64/ADGRG2

    Biochemical and Biophysical Research Communications 464:743–747.

    https://doi.org/10.1016/j.bbrc.2015.07.020

    • PubMed
    • Google Scholar
14. 1. Demberg LM
    2. Winkler J
    3. Wilde C
    4. Simon KU
    5. Schön J
    6. Rothemund S
    7. Schöneberg T
    8. Prömel S
    9. Liebscher I

    (2017) Activation of adhesion G protein-coupled receptors: agonist specificity of stachel sequence-derived peptides

    The Journal of Biological Chemistry 292:4383–4394.

    https://doi.org/10.1074/jbc.M116.763656

    • PubMed
    • Google Scholar
15. 1. Folts CJ
    2. Giera S
    3. Li T
    4. Piao X

    (2019) Adhesion G protein-coupled receptors as drug targets for neurological diseases

    Trends in Pharmacological Sciences 40:278–293.

    https://doi.org/10.1016/j.tips.2019.02.003

    • PubMed
    • Google Scholar
16. 1. Fukuzawa T
    2. Ishida J
    3. Kato A
    4. Ichinose T
    5. Ariestanti DM
    6. Takahashi T
    7. Ito K
    8. Abe J
    9. Suzuki T
    10. Wakana S
    11. Fukamizu A
    12. Nakamura N
    13. Hirose S

    (2013) Lung surfactant levels are regulated by ig-hepta/GPR116 by monitoring surfactant protein D

    PLOS ONE 8:e69451.

    https://doi.org/10.1371/journal.pone.0069451

    • PubMed
    • Google Scholar
17. 1. Gad AA
    2. Azimzadeh P
    3. Balenga N

    (2021) Conserved residues in the extracellular loop 2 regulate stachel-mediated activation of ADGRG2

    Scientific Reports 11:14060.

    https://doi.org/10.1038/s41598-021-93577-y

    • PubMed
    • Google Scholar
18. 1. Georgiadi A
    2. Lopez-Salazar V
    3. Merahbi RE
    4. Karikari RA
    5. Ma X
    6. Mourão A
    7. Klepac K
    8. Bühler L
    9. Alfaro AJ
    10. Kaczmarek I
    11. Linford A
    12. Bosma M
    13. Shilkova O
    14. Ritvos O
    15. Nakamura N
    16. Hirose S
    17. Lassi M
    18. Teperino R
    19. Machado J
    20. Scheideler M
    21. Dietrich A
    22. Geerlof A
    23. Feuchtinger A
    24. Blutke A
    25. Fischer K
    26. Müller TD
    27. Kessler K
    28. Schöneberg T
    29. Thor D
    30. Hornemann S
    31. Kruse M
    32. Nawroth P
    33. Pivovarova-Ramich O
    34. Pfeiffer AFH
    35. Sattler M
    36. Blüher M
    37. Herzig S

    (2021) Orphan GPR116 mediates the insulin sensitizing effects of the hepatokine FNDC4 in adipose tissue

    Nature Communications 12:2999.

    https://doi.org/10.1038/s41467-021-22579-1

    • PubMed
    • Google Scholar
19. 1. Gkountelias K
    2. Tselios T
    3. Venihaki M
    4. Deraos G
    5. Lazaridis I
    6. Rassouli O
    7. Gravanis A
    8. Liapakis G

    (2009) Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding

    Molecular Pharmacology 75:793–800.

    https://doi.org/10.1124/mol.108.052423

    • PubMed
    • Google Scholar
20. 1. Kishore A
    2. Purcell RH
    3. Nassiri-Toosi Z
    4. Hall RA

    (2016) Stalk-dependent and stalk-independent signaling by the adhesion G protein-coupled receptors GPR56 (ADGRG1) and BAI1 (ADGRB1)

    The Journal of Biological Chemistry 291:3385–3394.

    https://doi.org/10.1074/jbc.M115.689349

    • PubMed
    • Google Scholar
21. 1. Kishore A
    2. Hall RA

    (2017) Disease-associated extracellular loop mutations in the adhesion G protein-coupled receptor G1 (ADGRG1; GPR56) differentially regulate downstream signaling

    The Journal of Biological Chemistry 292:9711–9720.

    https://doi.org/10.1074/jbc.M117.780551

    • PubMed
    • Google Scholar
22. 1. Langenhan T

    (2019) Adhesion G protein-coupled receptors-candidate metabotropic mechanosensors and novel drug targets

    Basic & Clinical Pharmacology & Toxicology 126:5–16.

    https://doi.org/10.1111/bcpt.13223

    • PubMed
    • Google Scholar
23. 1. Le QT
    2. Lyons JJ
    3. Naranjo AN
    4. Olivera A
    5. Lazarus RA
    6. Metcalfe DD
    7. Milner JD
    8. Schwartz LB

    (2019) Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia

    The Journal of Experimental Medicine 216:2348–2361.

    https://doi.org/10.1084/jem.20190701

    • PubMed
    • Google Scholar
24. 1. Liebscher I
    2. Schön J
    3. Petersen SC
    4. Fischer L
    5. Auerbach N
    6. Demberg LM
    7. Mogha A
    8. Cöster M
    9. Simon KU
    10. Rothemund S
    11. Monk KR
    12. Schöneberg T

    (2014) A tethered agonist within the ectodomain activates the adhesion G protein-coupled receptors GPR126 and GPR133

    Cell Reports 9:2018–2026.

    https://doi.org/10.1016/j.celrep.2014.11.036

    • PubMed
    • Google Scholar
25. Conference

    1. Liessmann F
    2. Wilde C
    3. Wieprecht A
    4. Sierks M
    5. Schoeder CT
    6. Berndt S
    7. Meiler J
    8. Liebscher I

    (2021)

    Homology modeling of GPR114/ADGRG5 with rosetta elucidates possible interactions between ECL2 and GAIN domain

    Protein Sci. 2021 30:SUPPL 1 (113) – Conference abstract.

    • Google Scholar
26. 1. Lin HH
    2. Hsiao CC
    3. Pabst C
    4. Hébert J
    5. Schöneberg T
    6. Hamann J

    (2017) Adhesion gpcrs in regulating immune responses and inflammation

    Advances in Immunology 136:163–201.

    https://doi.org/10.1016/bs.ai.2017.05.005

    • PubMed
    • Google Scholar
27. 1. Lin X
    2. Li M
    3. Wang N
    4. Wu Y
    5. Luo Z
    6. Guo S
    7. Han GW
    8. Li S
    9. Yue Y
    10. Wei X
    11. Xie X
    12. Chen Y
    13. Zhao S
    14. Wu J
    15. Lei M
    16. Xu F

    (2020) Structural basis of ligand recognition and self-activation of orphan GPR52

    Nature 579:152–157.

    https://doi.org/10.1038/s41586-020-2019-0

    • PubMed
    • Google Scholar
28. 1. Luo R
    2. Jeong SJ
    3. Yang A
    4. Wen M
    5. Saslowsky DE
    6. Lencer WI
    7. Araç D
    8. Piao X

    (2014) Mechanism for adhesion G protein-coupled receptor GPR56-mediated rhoa activation induced by collagen III stimulation

    PLOS ONE 9:e100043.

    https://doi.org/10.1371/journal.pone.0100043

    • PubMed
    • Google Scholar
29. 1. Mathiasen S
    2. Palmisano T
    3. Perry NA
    4. Stoveken HM
    5. Vizurraga A
    6. McEwen DP
    7. Okashah N
    8. Langenhan T
    9. Inoue A
    10. Lambert NA
    11. Tall GG
    12. Javitch JA

    (2020) G12/13 is activated by acute tethered agonist exposure in the adhesion GPCR ADGRL3

    Nature Chemical Biology 16:1343–1350.

    https://doi.org/10.1038/s41589-020-0617-7

    • PubMed
    • Google Scholar
30. Preprint

    1. Mitgau J
    2. Franke J
    3. Schinner C
    4. Stephan G
    5. Berndt S
    6. Placantonakis DG
    7. Kalwa H
    8. Spindler V
    9. Wilde C
    10. Liebscher I

    (2022) The N Terminus of Adhesion G Protein-Coupled Receptor GPR126/ADGRG6 as Allosteric Force Integrator

    bioRxiv.

    https://doi.org/10.1101/2021.09.13.460127

    • Google Scholar
31. 1. Müller A
    2. Winkler J
    3. Fiedler F
    4. Sastradihardja T
    5. Binder C
    6. Schnabel R
    7. Kungel J
    8. Rothemund S
    9. Hennig C
    10. Schöneberg T
    11. Prömel S

    (2015) Oriented cell division in the C. elegans embryo is coordinated by G-protein signaling dependent on the adhesion GPCR LAT-1

    PLOS Genetics 11:e1005624.

    https://doi.org/10.1371/journal.pgen.1005624

    • PubMed
    • Google Scholar
32. 1. Naranjo AN
    2. Bandara G
    3. Bai Y
    4. Smelkinson MG
    5. Tobío A
    6. Komarow HD
    7. Boyden SE
    8. Kastner DL
    9. Metcalfe DD
    10. Olivera A

    (2020) Critical signaling events in the mechanoactivation of human mast cells through P.C492Y-ADGRE2

    The Journal of Investigative Dermatology 140:2210–2220.

    https://doi.org/10.1016/j.jid.2020.03.936

    • PubMed
    • Google Scholar
33. 1. Nazarko O
    2. Kibrom A
    3. Winkler J
    4. Leon K
    5. Stoveken H
    6. Salzman G
    7. Merdas K
    8. Lu Y
    9. Narkhede P
    10. Tall G
    11. Prömel S
    12. Araç D

    (2018) A comprehensive mutagenesis screen of the adhesion GPCR latrophilin-1/ADGRL1

    IScience 3:264–278.

    https://doi.org/10.1016/j.isci.2018.04.019

    • PubMed
    • Google Scholar
34. 1. Niaudet C
    2. Hofmann JJ
    3. Mäe MA
    4. Jung B
    5. Gaengel K
    6. Vanlandewijck M
    7. Ekvärn E
    8. Salvado MD
    9. Mehlem A
    10. Al Sayegh S
    11. He L
    12. Lebouvier T
    13. Castro-Freire M
    14. Katayama K
    15. Hultenby K
    16. Moessinger C
    17. Tannenberg P
    18. Cunha S
    19. Pietras K
    20. Laviña B
    21. Hong J
    22. Berg T
    23. Betsholtz C

    (2015) Gpr116 receptor regulates distinctive functions in pneumocytes and vascular endothelium

    PLOS ONE 10:e0137949.

    https://doi.org/10.1371/journal.pone.0137949

    • PubMed
    • Google Scholar
35. 1. OBrien PJ
    2. Molino M
    3. Kahn M
    4. Brass LF

    (2001) Protease activated receptors: theme and variations

    Oncogene 20:1570–1581.

    https://doi.org/10.1038/sj.onc.1204194

    • PubMed
    • Google Scholar
36. 1. Olaniru OE
    2. Persaud SJ

    (2019) Adhesion G-protein coupled receptors: implications for metabolic function

    Pharmacology & Therapeutics 198:123–134.

    https://doi.org/10.1016/j.pharmthera.2019.02.012

    • PubMed
    • Google Scholar
37. 1. Omasits U
    2. Ahrens CH
    3. Müller S
    4. Wollscheid B

    (2014) Protter: interactive protein feature visualization and integration with experimental proteomic data

    Bioinformatics 30:884–886.

    https://doi.org/10.1093/bioinformatics/btt607

    • PubMed
    • Google Scholar
38. 1. Peeters MC
    2. Fokkelman M
    3. Boogaard B
    4. Egerod KL
    5. van de Water B
    6. IJzerman AP
    7. Schwartz TW

    (2015) The adhesion G protein-coupled receptor G2 (ADGRG2/GPR64) constitutively activates SRE and NFκB and is involved in cell adhesion and migration

    Cellular Signalling 27:2579–2588.

    https://doi.org/10.1016/j.cellsig.2015.08.015

    • PubMed
    • Google Scholar
39. 1. Peeters M.C
    2. Mos I
    3. Lenselink EB
    4. Lucchesi M
    5. IJzerman AP
    6. Schwartz TW

    (2016) Getting from A to B-exploring the activation motifs of the class B adhesion G protein-coupled receptor subfamily G member 4/GPR112

    FASEB Journal 30:1836–1848.

    https://doi.org/10.1096/fj.201500110

    • PubMed
    • Google Scholar
40. 1. Ping YQ
    2. Xiao P
    3. Yang F
    4. Zhao RJ
    5. Guo SC
    6. Yan X
    7. Wu X
    8. Zhang C
    9. Lu Y
    10. Zhao F
    11. Zhou F
    12. Xi YT
    13. Yin W
    14. Liu FZ
    15. He DF
    16. Zhang DL
    17. Zhu ZL
    18. Jiang Y
    19. Du L
    20. Feng SQ
    21. Schöneberg T
    22. Liebscher I
    23. Xu HE
    24. Sun JP

    (2022) Structural basis for the tethered peptide activation of adhesion gpcrs

    Nature 604:763–770.

    https://doi.org/10.1038/s41586-022-04619-y

    • PubMed
    • Google Scholar
41. 1. Prömel S
    2. Frickenhaus M
    3. Hughes S
    4. Mestek L
    5. Staunton D
    6. Woollard A
    7. Vakonakis I
    8. Schöneberg T
    9. Schnabel R
    10. Russ AP
    11. Langenhan T

    (2012) The GPS motif is a molecular switch for bimodal activities of adhesion class G protein-coupled receptors

    Cell Reports 2:321–331.

    https://doi.org/10.1016/j.celrep.2012.06.015

    • PubMed
    • Google Scholar
42. 1. Qu X
    2. Qiu N
    3. Wang M
    4. Zhang B
    5. Du J
    6. Zhong Z
    7. Xu W
    8. Chu X
    9. Ma L
    10. Yi C
    11. Han S
    12. Shui W
    13. Zhao Q
    14. Wu B

    (2022) Structural basis of tethered agonism of the adhesion gpcrs ADGRD1 and ADGRF1

    Nature 604:779–785.

    https://doi.org/10.1038/s41586-022-04580-w

    • PubMed
    • Google Scholar
43. 1. Scholz N
    2. Guan C
    3. Nieberler M
    4. Grotemeyer A
    5. Maiellaro I
    6. Gao S
    7. Beck S
    8. Pawlak M
    9. Sauer M
    10. Asan E
    11. Rothemund S
    12. Winkler J
    13. Prömel S
    14. Nagel G
    15. Langenhan T
    16. Kittel RJ

    (2017) Mechano-dependent signaling by latrophilin/CIRL quenches camp in proprioceptive neurons

    eLife 6:e28360.

    https://doi.org/10.7554/eLife.28360

    • PubMed
    • Google Scholar
44. 1. Scholz N

    (2018) Cancer cell mechanics: adhesion G protein-coupled receptors in action?

    Frontiers in Oncology 8:59.

    https://doi.org/10.3389/fonc.2018.00059

    • PubMed
    • Google Scholar
45. 1. Seeley S
    2. Covic L
    3. Jacques SL
    4. Sudmeier J
    5. Baleja JD
    6. Kuliopulos A

    (2003) Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding

    Chemistry & Biology 10:1033–1041.

    https://doi.org/10.1016/j.chembiol.2003.10.014

    • PubMed
    • Google Scholar
46. 1. Slaymaker IM
    2. Gao L
    3. Zetsche B
    4. Scott DA
    5. Yan WX
    6. Zhang F

    (2016) Rationally engineered cas9 nucleases with improved specificity

    Science 351:84–88.

    https://doi.org/10.1126/science.aad5227

    • PubMed
    • Google Scholar
47. 1. Stoveken HM
    2. Hajduczok AG
    3. Xu L
    4. Tall GG

    (2015) Adhesion G protein-coupled receptors are activated by exposure of a cryptic tethered agonist

    PNAS 112:6194–6199.

    https://doi.org/10.1073/pnas.1421785112

    • PubMed
    • Google Scholar
48. 1. Sun Y
    2. Zhang D
    3. Ma ML
    4. Lin H
    5. Song Y
    6. Wang J
    7. Ma C
    8. Yu K
    9. An W
    10. Guo S
    11. He D
    12. Yang Z
    13. Xiao P
    14. Hou G
    15. Yu X
    16. Sun JP

    (2021) Optimization of a peptide ligand for the adhesion GPCR ADGRG2 provides a potent tool to explore receptor biology

    The Journal of Biological Chemistry 296:100174.

    https://doi.org/10.1074/jbc.RA120.014726

    • PubMed
    • Google Scholar
49. 1. Valerius MT
    2. Patterson LT
    3. Witte DP
    4. Potter SS

    (2002) Microarray analysis of novel cell lines representing two stages of metanephric mesenchyme differentiation

    Mechanisms of Development 112:219–232.

    https://doi.org/10.1016/s0925-4773(02)00008-4

    • PubMed
    • Google Scholar
50. 1. Vizurraga A
    2. Adhikari R
    3. Yeung J
    4. Yu M
    5. Tall GG

    (2020) Mechanisms of adhesion G protein-coupled receptor activation

    The Journal of Biological Chemistry 295:14065–14083.

    https://doi.org/10.1074/jbc.REV120.007423

    • PubMed
    • Google Scholar
51. 1. Wang H
    2. Yang H
    3. Shivalila CS
    4. Dawlaty MM
    5. Cheng AW
    6. Zhang F
    7. Jaenisch R

    (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/cas-mediated genome engineering

    Cell 153:910–918.

    https://doi.org/10.1016/j.cell.2013.04.025

    • PubMed
    • Google Scholar
52. 1. Wheatley M
    2. Wootten D
    3. Conner MT
    4. Simms J
    5. Kendrick R
    6. Logan RT
    7. Poyner DR
    8. Barwell J

    (2012) Lifting the lid on gpcrs: the role of extracellular loops

    British Journal of Pharmacology 165:1688–1703.

    https://doi.org/10.1111/j.1476-5381.2011.01629.x

    • PubMed
    • Google Scholar
53. 1. Wilde C
    2. Fischer L
    3. Lede V
    4. Kirchberger J
    5. Rothemund S
    6. Schöneberg T
    7. Liebscher I

    (2016) The constitutive activity of the adhesion GPCR GPR114/ADGRG5 is mediated by its tethered agonist

    FASEB Journal 30:666–673.

    https://doi.org/10.1096/fj.15-276220

    • PubMed
    • Google Scholar
54. 1. Wink LH
    2. Baker DL
    3. Cole JA
    4. Parrill AL

    (2019) A benchmark study of loop modeling methods applied to G protein-coupled receptors

    Journal of Computer-Aided Molecular Design 33:573–595.

    https://doi.org/10.1007/s10822-019-00196-x

    • PubMed
    • Google Scholar
55. 1. Xiao P
    2. Guo S
    3. Wen X
    4. He QT
    5. Lin H
    6. Huang SM
    7. Gou L
    8. Zhang C
    9. Yang Z
    10. Zhong YN
    11. Yang CC
    12. Li Y
    13. Gong Z
    14. Tao XN
    15. Yang ZS
    16. Lu Y
    17. Li SL
    18. He JY
    19. Wang C
    20. Zhang L
    21. Kong L
    22. Sun JP
    23. Yu X

    (2022) Tethered peptide activation mechanism of the adhesion gpcrs ADGRG2 and ADGRG4

    Nature 604:771–778.

    https://doi.org/10.1038/s41586-022-04590-8

    • PubMed
    • Google Scholar
56. 1. Yang MY
    2. Hilton MB
    3. Seaman S
    4. Haines DC
    5. Nagashima K
    6. Burks CM
    7. Tessarollo L
    8. Ivanova PT
    9. Brown HA
    10. Umstead TM
    11. Floros J
    12. Chroneos ZC
    13. St Croix B

    (2013) Essential regulation of lung surfactant homeostasis by the orphan G protein-coupled receptor GPR116

    Cell Reports 3:1457–1464.

    https://doi.org/10.1016/j.celrep.2013.04.019

    • PubMed
    • Google Scholar
57. 1. Yang H
    2. Wang H
    3. Jaenisch R

    (2014) Generating genetically modified mice using CRISPR/cas-mediated genome engineering

    Nature Protocols 9:1956–1968.

    https://doi.org/10.1038/nprot.2014.134

    • PubMed
    • Google Scholar
58. 1. Yuan CL
    2. Hu YC

    (2017) A transgenic core facility’s experience in genome editing revolution

    Advances in Experimental Medicine and Biology 1016:75–90.

    https://doi.org/10.1007/978-3-319-63904-8_4

    • PubMed
    • Google Scholar
59. 1. Zaidman NA
    2. Tomilin VN
    3. Hassanzadeh Khayyat N
    4. Damarla M
    5. Tidmore J
    6. Capen DE
    7. Brown D
    8. Pochynyuk OM
    9. Pluznick JL

    (2020) Adhesion-GPCR gpr116 (ADGRF5) expression inhibits renal acid secretion

    PNAS 117:26470–26481.

    https://doi.org/10.1073/pnas.2007620117

    • PubMed
    • Google Scholar
60. 1. Zhu B
    2. Luo R
    3. Jin P
    4. Li T
    5. Oak HC
    6. Giera S
    7. Monk KR
    8. Lak P
    9. Shoichet BK
    10. Piao X

    (2019) GAIN domain-mediated cleavage is required for activation of G protein-coupled receptor 56 (GPR56) by its natural ligands and a small-molecule agonist

    The Journal of Biological Chemistry 294:19246–19254.

    https://doi.org/10.1074/jbc.RA119.008234

    • PubMed
    • Google Scholar

Decision letter after peer review:

Thank you for submitting your article "Activation of GPR116/ADGRF5 by its tethered agonist requires key amino acids in extracellular loop 2 of the transmembrane region" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Nancy Carrasco as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Antony Boucard (Reviewer #3).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

As detailed in the reviewer comments below, reviewers agree on these essential revisions:

– Cell expression data and quantification for mutants.

– Re-interpretation of the results for the ECL mutations on GPR116 signaling activity.

– Further analysis and re-interpretation of the in vivo mouse experiments.

­– Discussion of previously known mutations about how tethered agonist peptide activates the receptor in introduction, proposed model and discussion.

Reviewer 1:

1. Why this abbreviation? "exogenous synthetic peptides (GAP)". It does not fit to the open name.

2. "the cleavage at the GPS site and such receptors may be activated by structural changes not requiring the dissociation of the NTF and CTF." I am not sure if this sentence is needed for the intro.

3. Intro is too long. Authors should condense it into the most important points.

4. Figure 8A. Currently the figure is poorly done. Residues are not labeled well and some residues are shown but not labeled.

5. Figure 1B:

a. The band around 45 kD is a significant band is not mentioned in the text.

b. it is concerning how much intracellular receptor there is and how that may be affecting results (bright green blobs inside cells). Perhaps this is receptor which is internalized after residence at the plasma membrane, or misfolded receptor.

6. Figure 3B: The authors quantify variant expression using whole cell lysates. Yet, if figure 1B is representative, there may be a significant fraction of their GPR116 proteins that are not available on the cell surface, affecting the interpretation of their data in this figure. I would suggest they measure cell surface expression of their proteins and not whole cell lysates. See point 11.

7. Figure 3C: If there is a large amount of internalized/misfolded receptor as seen in Figure 1B, these assay results should be normalized to the level of protein expressed on the surface of the cell, not expression levels from total lysate. See point 11.

8. Figure 3D: not stated how many experiments were performed.

9. Figure 3E: N=1 experiment for IP1 accumulation assay not acceptable. N=2 for calcium assay not preferred. N=3 for both experiments is preferred.

10. In Figure 3E, there are two columns for the calcium EC50. It's not clear which one is the EC50 and what the other column is.

11. Line 235-240: The constructs (N-FLAG/mCherry-CTF-C) described are not detailed in the methods, but referenced. The referenced paper does not describe how long linker regions are. A sufficiently long or flexible linker region between the N-terminal FLAG or mCherry and the tethered agonist could still allow for the tethered agonist to bury within an orthosteric pocket on the aGPCR. Thus, this speculation is not valid, and it actually contradicts their structural model in figure 8A, which shows the tethered agonist binding pocket penetrating deep into the 7TM core of the receptor. Or is this really what is shown in Figure 8? Figure 8 is not clear and needs work with a new model.

12. Line 263- expression levels are claimed to be similar, but they do not look similar from what is shown in Figure 4E. It does not even look like there is any expression for the WT "mFL" protein. They need to quantify it somehow to compare the expression levels. If there are differences in expression their data must be normalized using expression levels.

13. Line 264-265: "… alanine mutations introduced into hFL abolished response to GAP14 while not affecting protein or plasma membrane localization (supp. Figure 6)". However, if you look at supplemental figure 6B, their mutant proteins express much less compared to wild type. In addition, it is not easy to compare membrane expression in figure supp 6C without some method of quantification, but the mutant expression again looks lower than WT. This means their data should be normalized to expression levels, and their new results may actually be different than they are showing in supp. 6A.

14. Line 336: Their expression levels are clearly different from supp. Figure 8. They have to normalize to expression levels.

15. Line 363: "all mutants expressed well": it is difficult to compare without some type of quantification.

16. Line 364/365: It is a stretch to say that hCTFbaxG1011K "resembles mCTFbax". Please reword to something like " the EC50 of hCTFbaxG1011K is shifted towards mCTFbax".

17. Figure 5: Data must be collected in three independent experiments, and it is not acceptable to not show data.

18. Figure 6 and supplemental Figure 10: it is hard to evaluate their claims without quantification of their expression and normalizing their data to their expression.

19. Figure 6B: Data must be collected in three independent experiments. it is not clear how this data was collected. Does "repeat" mean independent experiments?

20. Figure 7 A and B: Data must be collected in three independent experiments

21. Discussion could be trimmed as well.

Reviewer 2:

1. To address points 2, 5 and 6 in my public review, the authors should perform additional quantification of data and/or statistical comparisons.

2. To address points 1, 3, 4, and 7 in my public review, the authors should either add further data that supports their claims (if they want to maintain the interpretation of their data as currently written) or alternatively they should alter the discussion of their findings if some of their interpretations cannot be more strongly supported by additional data.

Reviewer 3:

1. Title is confusing when referring to "… in extracellular loop 2 of the transmembrane region" and should preferably indicate "… in extracellular loop 2 and the transmembrane region".

2. The authors should analyze the role of the highly conserved Histidine residue in position 991 by generating at least one other substitution mutant with a conservative amino acid. A phenotypic rescue strategy could then be conducted by overexpressing the conservative mutant on the GPR116 knock-out background (previously generated by the research team). A parallel in vitro validation of the receptor mutant in HEK293 cells can be achieved to compare activation by GAP peptides, constitutive activity, expression and cleavage parameters all of which would help reinforce the authors' hypothesis on whether it is a lack of cleavage rather than the substitution of a highly conserved residue that is causing the described phenotypes.

3. Authors should provide a more detailed characterization of the GPR116 H991A/H991A mouse line. First, tissue expression of the mutated receptor should be assessed to discard the probability of a loss-of-function phenotype due to a lack of expression. Second, a direct comparison of AT2 cells secretion parameters should be included for the different genotypes (GPR116+/+, GPR116 -/-, GPR116 H991A/H991A), in order to gain direct mechanistic insights into genotype-linked phenotypes and evaluate the degree of loss-of-function phenotypes between GRP116-deficient mice and cleavage-deficient mice. Third, phospholipid homeostasis parameters should be tested further using AT2 cells from these mice in presence and absence of ATP stimuli (phospholipid secretion, phospholipid uptake).

4. Authors should determine expression levels for each receptor constructs in order to normalize their functional data accordingly. N-terminally Flag-tagged constructs provide an excellent opportunity to evaluate membrane exposure of mCTF receptors from the cell surface of HEK293 cells. This can be achieved by using flow cytometry (as performed in Supp Figure 7 for quantifying N-terminal mCherry signal) quantifying cell-surface fluorescence intensity of cell populations expressing respective receptor mutants which can be detected with anti-Flag antibody and fluorophore-coupled secondary antibody. Alternatively, a cell ELISA can be conducted using the same strategy but revealing with horseradish peroxidase substrates. As for C-terminally V5-tagged constructs, they can be analyzed also by flow cytometry coupled to immunofluorescence in order to obtain total protein expression levels as the positioning of the tag does not allow to make a distinction between subcellular compartments. For western blotting experiments, although band intensities can be visually approximated from western blot images, we highly recommend that authors make use of pixel intensity-based quantification software to monitor band intensities normalized using housekeeping proteins as loading controls.

5. P.11, the authors conducted activation assays rather than binding assays and thus should refrain from inferring that " … set out to determine the region of the receptor to which the tethered agonist binds…". This sentence should be rephrased in order to better reflect the correlation that the authors try to establish using their structure-function assays strategy. Additionally, every mention of a binding site determination throughout the manuscript should be nuanced with this aspect in mind.

6. In their systematic characterization of critical residues by conservative substitutions the authors have dismissed the T1240 position which leaves this seemingly systematic approach incomplete. In order to show consistency, we recommend that they generate a Threonine to Serine replacement at this position and include the analysis in the manuscript.

7. In the generation of basal activity-null constructs ("bax" constructs), it is not clear why a different engineering strategy was adopted to generate the human versus mouse version. The authors should at least allude to it in the manuscript by shortly explaining or indicating if technical or circumstantial elements played a role in designing these different versions, or if other versions of hCTFbax where in fact designed but did not result in reduction in constitutive activity.

8. For consistency purposes, the authors should evaluate all mGPR116 full-length versions of receptor mutants modifying key ECL residues with a version of full-length mGPR116 also containing an intracellular V5 epitope tag to discard any collateral effects due to the insertion of a tag that could potentially disrupt intracellular coupling events. This is particularly important giving that the human versions containing an intracellular V5 epitope (hFL versions) display expression differences (Supp Figure 6B).

9. In order to allow for a more comprehensive reading, the authors should briefly explain in the text what their strategy was when using different GAP peptides interchangeably for the different assays.

10. The manuscript would greatly benefit from the inclusion of a table reporting the EC50 values obtained for all calcium transient experiments as this would allow for a more accurate comparison between the different conditions.

11. Methodology: Immunocytochemistry- Please describe the reagents and their concentrations used for fixation, permeabilization and blocking methods. Calcium transients- Please briefly specify M3R activation protocol.

12. P.15, Please correct the sentence as it contains a repetitive portion: "Conservative exchanges for the three other critical amino acids still yielded inactive receptors… all yielded inactive receptors".

13. P16, please correct "… high probability of interactint…".

14. P.18, please correct "… have been have been…".

15. P.20, please correct "… structural aspects aGPCRs activation, …".

16. Figure 2 panels C and D, please include data obtained for control mice.

17. Figure 2: Please indicate data representation (mean), statistical error and analysis for panels C and D in figure legend.

18. For reproducibility purposes we recommend that the experimental set displayed in Figure 3 panel E for calcium and IP1 accumulation assays, be completed with at least n = 3 and after doing so, please indicate in figure legend the number of experimental repetitions, data/error type and statistical analysis conducted. Also, please indicate in the table the units used for IP1 accumulation assays as well as the respective concentration of indicated activating peptides that were used in this assay.

19. Figure 3 panel D, please indicate in figure legend the proper description of data representation (mean), error and statistical analysis as well as representativity (n of experiments). Also, please include in the panel the "dash line" which is mentioned in the figure legend.

20. Figure 3 panel B, please identify the mCTF lane as such.

21. Figure 8 panel A, please indicate which critical residues are represented by the other spheres at the top of TM3, middle and top of TM2, bottom of TM5, top of TM7 and/or TM2.

22. Please provide scale bars for all microscopy images since some images appear to have been captured with a different zoom magnification (For example Supp. Figure 9).

23. Figure legend for Supp Figure 6, please correct "HEK296" for "HEK293".

24. Figure legend Supp. Figure 10, please indicate if results describe transient or stable HEK293 transfections.

25. Supp. Figure 11, the table's second column title indicates "extracellular part of the NTF…" but should rather say "N-terminal part of the CTF…".

26. Supp. Figure 11, please indicate with an asterisk the GPS cleavage-deficient aGPCR such as ADGRG5.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "Activation of GPR116/ADGRF5 by its tethered agonist requires key amino acids in extracellular loop 2 and the transmembrane region" for further consideration by eLife. Your revised article has been evaluated by Suzanne Pfeffer (Senior Editor), a Reviewing Editor, and the original reviewers.

We are most intrigued by the work you have reported about the importance of autoproteolysis for the GPR116 function in vivo. Please address the additional issues that the reviewers raised below in their comments including:

– Please discuss the new GPR116 paper that describes a new ligand.

– Clarify the points about reproducibility.

– Revise the title so the story can be better appreciated by the broad audience of eLife.

– Rearrange the adhesion GPCR schematic in Figure 1 to correctly indicate the adhesion GPCR domains, including the GAIN domain and the GPS motif which is a peptide inside of the GAIN domain. Please also correct the same issue in the instruction.

– Provide a GPR116 TM/ peptide model based on the new adhesion GPCR structures. The current model is based on a class B family member.

More detailed comments can be found below, and we look forward to receiving your revised manuscript.

Reviewer #2 (Recommendations for the authors):

The authors were very responsive to the reviewers' comments and addressed all of the reviewers' concerns. The textual changes and new data added by the authors have significantly strengthened the manuscript.

One additional comment I would like to make is that after the review of the original draft of this manuscript in Spring 2021, a paper was published reporting the secreted protein FNDC4 as a ligand for GPR116 (Georgiadi et al., Nat. Comm., 2021). This work is not mentioned in the present manuscript, and indeed the authors have a statement in the penultimate paragraph of their Introduction stating, "Still considered an orphan aGPCR, GPR116 has been proposed…".

Is GPR116 still an orphan? It is understood that FNDC4 cannot be considered a definitive ligand for GPR116 until other groups have had a chance to confirm (or refute) the findings of Georgiadi and colleagues, but nonetheless, it seems that the work of Georgiadi et al. is highly relevant to the studies described in the present manuscript and therefore should at least be mentioned at some point.

Along these same lines, it is terrific that the authors of the present manuscript made the effort to cite the recent wave of cryo-EM studies on aGPCRs and place their findings in the context of those new structural studies. In a similar vein, it would also be appropriate for the authors to cite the recently-published work of Georgiadi et al. and discuss how these findings may be relevant to the authors' own findings of the activation mechanism of GPR116.

Reviewer #3 (Recommendations for the authors):

I am satisfied with the authors' response to my original comments, but I have some suggestions that would need to be addressed for ease of reading, accuracy, and reproducibility purposes regarding the newly added data in this revised version:

1. To avoid confusion, I would suggest adding "Cell surface expression (Mean fluorescence)" as the title for the Y axis of all graphs reporting results from surface exposed epitope in flow cytometry (Flag): Figure 3C, Figure 4 D, Figure 4 Supp figure 4D-E.

2. Likewise, I would suggest indicating "Total expression (mean fluorescence)" as the Y-axis title of all graphs reporting flow cytometry results from intracellular epitopes (V5/mCherry). Figure 4E, Figure 4 Supp Figure 4B.

3. Refrain from using the terms “membrane expression” when the methodology that has been used does not allow this determination exclusively since the immunocytochemistry protocol, as currently described in the methods section, involves a permeabilization step. This is the case in Figure 4 Supp figure 3A and 3C.

4. Please complete the newly added data with the corresponding information on reproducibility parameters (# of independent experiments, define error bars). Error bar descriptions and/or # of independent experiments are missing for various figures involving functional assays or for expression quantifications by western blot or flow cytometry (western blot quantifications do not display errors? Was it done just once? Justify if this is the case as stable cell lines can show decaying expression with time). These include: Figure 3F; Figure 3 Supp Figure 1 and 2; Figure 4; Figure 4 Supp Figure 1B,3B,3D, 4B-E; Figure 5A,B,E; Figure 5 Supp Figure 1B; Figure 6B-C; Figure 6 Supp Figure 1C; Figure 7; Figure 10 (error is SD or SEM?).

5. It seems that flow cytometry experiments were performed only once, indicate if this is not the case.

6. For flow cytometry experiments, indicate the number of events analyzed in the methods section.

7. The use of the term “biological replicates” seems incorrect throughout figure legends as they seem to indicate technical replicates instead. One experiment done at the same time is a n=1 that might include various replicates of each different groups, considered technical replicates; when the same experiment is done more than once at different times experiments are considered biological replicates. For example, the legend for Figure 4F indicates 3 independent experiments with 4 biological replicates but instead should read as 3 independent experiments done in quadruplicates or 4 technical replicates. Please revise where relevant and correct if this is the case or add if it is missing (For example Fig3F, Figure 3 Sup Figure 1, and others are missing replicates data).

8. Indicate where relevant when experiments are technical replicates instead of biological replicates. Add information about statistical significance where data represent biological replicates.

9. Because the data seems more relevant to the reader in this case, please interchange current panel E in Figure 4 with surface expression graphs for remaining mutants displayed in this figure depicted in Figure 4 Supp Figure 4 D-E.

10. Line 660, please correct the antibody incubation time indicating 230 min.

11. Indicate “% IP1 conversion” as the Y-axis title for all corresponding graphs.

12. Note that no cell surface data expression is present for hFL-T1240A and is also missing for various hFL or hCTFbax or mCTF mutants. If data cannot be included at this stage, please include a brief comment in the manuscript to the effect of why this is the case in each section where the data is missing.

13. Figures 9 and 10 seem more suited for the supplementary section.

Essential revisions:

As detailed in the reviewer comments below, reviewers agree on these essential revisions:

– Cell expression data and quantification for mutants.

We have addressed these points by adding additional quantification of cell surface expression for the key functional mutants identified in this study, as permitted by the N-terminal or C-terminal epitope tags present in the expression constructs (Figure 3C; Figure 4C,D and E; Figure 4 supplement figure 3D; Figure 4 supplement figure 4C,D and E; Figure 5 supplement figure 1B; Figure 6 supplement figure 1C). We have also added additional statistical analyses for all the dose-response curves (Figure 3E and F, Figure 4B,F and G, Figure 5B and E, Figure 6B and C).

– Re-interpretation of the results for the ECL mutations on GPR116 signaling activity.

We rephrased these aspects as requested in the Results section and discussed their relevance in context of the presented and published data.

– Further analysis and re-interpretation of the in vivo mouse experiments.

We have included additional data demonstrating comparable surfactant lipid accumulation in the bronchoalveolar lavage fluid of H991A and WT mice (Figure 2A), added additional data for ex vivo activation of isolated H991A and WT alveolar epithelial cells (Figure 2C and D) and altered our interpretation of the in vivo experiments in the Results and Discussion sections as requested.

­– Discussion of previously known mutations about how tethered agonist peptide activates the receptor in introduction, proposed model and discussion.

We have included discussion of mechanisms of tethered agonist peptide activation of the receptor from published data of additional aGPCRs in the Introduction, Results and Discussion sections, as requested.

Reviewer 1:

1. Why this abbreviation? "exogenous synthetic peptides (GAP)". It does not fit to the open name.

We use the term GAP (GPCR-activating peptide) to refer the numerous synthetic peptides used in this study. We have added an explanation of the GAP abbreviation to the text.

2. "the cleavage at the GPS site and such receptors may be activated by structural changes not requiring the dissociation of the NTF and CTF." I am not sure if this sentence is needed for the intro.

We have changed this sentence in the Introduction.

3. Intro is too long. Authors should condense it into the most important points.

We condensed the Introduction as requested. (1333 words down to 938).

4. Figure 8A. Currently the figure is poorly done. Residues are not labeled well and some residues are shown but not labeled.

We have edited Figure 8 for clarity and added additional data including modeling of GPR116 with the glucagon receptor and its cognate ligand.

5. Figure 1B:

a. The band around 45 kD is a significant band is not mentioned in the text.

This is a non-specific band since it is present in all three lanes, including the non-transfected (NTF) control. We have edited the panel to highlight this band with an asterisk and refer to such in the figure legend.

b. it is concerning how much intracellular receptor there is and how that may be affecting results (bright green blobs inside cells). Perhaps this is receptor which is internalized after residence at the plasma membrane, or misfolded receptor.

We consistently observe some degree of intracellular staining in cells transfected with GPR116, more so with the CTF constructs than with the full length receptor, the mechanism for which is presently unknown. However, desensitization experiments did not show decrease of activity of the mFL construct over a 2 hour time frame (not shown). Peptide-induced receptor internalization studies are challenging for this reason as well. That said, the degree of intracellular staining is similar for WT and the H991A mutant, so if signaling were affected by localization within the cell one would predict it would be affected similarly for both constructs. HEK293 cells are a strong expression system for CMV promoter-driven genes and indeed a strong receptor response is observed in functional assays, suggesting high levels of appropriate expression and localization. Further we do know that GPCRs exogenously expressed in HEK293 cells can rapidly reach receptor reserve (i.e. maximal response is reached without complete receptor occupancy – see e.g. the review from Buchwald 2019: Frontiers | A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data | Pharmacology (frontiersin.org)), implicating that lower membrane expression can be sufficient to reach maximal response.

6. Figure 3B: The authors quantify variant expression using whole cell lysates. Yet, if figure 1B is representative, there may be a significant fraction of their GPR116 proteins that are not available on the cell surface, affecting the interpretation of their data in this figure. I would suggest they measure cell surface expression of their proteins and not whole cell lysates. See point 11.

We have quantitated cell surface expression of the key N-term FLAG and ECL variants critical for GPR116 activation using FACS analysis of non-permeabilized FLAG-stained cells (Figure 3C and Figure 4D and E, Figure 4 – supplement figure 4D and E, respectively). These data demonstrate similar levels of cell surface protein expression amongst the wild-type and mutated receptors, except for 3 mutants with conservative amino acid changes which is discussed in the Results section.

7. Figure 3C: If there is a large amount of internalized/misfolded receptor as seen in Figure 1B, these assay results should be normalized to the level of protein expressed on the surface of the cell, not expression levels from total lysate. See point 11.

Expression levels of GPR116 protein present at the cell surface have been performed (Figure 3C). Please see response to inquiry 6 above.

8. Figure 3D: not stated how many experiments were performed.

The graph in the original submission was from a single experiment. We have now added additional data for the basal activity and the GAP14 super-activation along with appropriate statistical analyses.

9. Figure 3E: N=1 experiment for IP1 accumulation assay not acceptable. N=2 for calcium assay not preferred. N=3 for both experiments is preferred.

We have removed the IP1 data and generated additional calcium assay data for a total of n=3 experiments. Two of the peptides (S996A and D1002A) were degraded and could not be re-tested for a triplicate value in this assay.

10. In Figure 3E, there are two columns for the calcium EC50. It's not clear which one is the EC50 and what the other column is.

We have performed an additional replicate for all peptides, except for S996A and D1002A for reasons stated in query 9 above, included statistical analysis and edited the layout of this figure for enhanced clarity.

11. Line 235-240: The constructs (N-FLAG/mCherry-CTF-C) described are not detailed in the methods, but referenced. The referenced paper does not describe how long linker regions are. A sufficiently long or flexible linker region between the N-terminal FLAG or mCherry and the tethered agonist could still allow for the tethered agonist to bury within an orthosteric pocket on the aGPCR. Thus, this speculation is not valid, and it actually contradicts their structural model in figure 8A, which shows the tethered agonist binding pocket penetrating deep into the 7TM core of the receptor. Or is this really what is shown in Figure 8? Figure 8 is not clear and needs work with a new model.

In the tagged constructs, the FLAG or mCherry tags are located immediately downstream of the ATG start site and a prolactin signal sequence, in frame with the coding sequence for GPR116 with no linker regions. We have included this information in the revised Methods section.

In addition, we have performed a structural alignment of a GPR116 homology model with the GLP1 receptor in complex with its ligand glucagon (Figure 8D). This analysis revealed that the N terminus of glucagon overlaps with the largest binding site of GPR116, suggesting that a peptide is capable of binding, at least partially, to the binding site we proposed. We adapted the text accordingly and attempted to make the point with more clarity.

12. Line 263- expression levels are claimed to be similar, but they do not look similar from what is shown in Figure 4E. It does not even look like there is any expression for the WT "mFL" protein. They need to quantify it somehow to compare the expression levels. If there are differences in expression their data must be normalized using expression levels.

The WT mFL clone used in the original figure was not tagged, therefore we have redone all parts of this figure using a V5-tagged mouse FL clone 1D8 as the control (Figure 4E,F and Figure 4 supplement figure 3A). Receptor expression was quantified by V5 flow cytometry and shows higher expression of the mutants than the control reference construct. As this tag is intracellular on the C-terminus, only total expression can be quantified. It is complemented by immunocytochemistry data to demonstrate localization of the protein to the plasma membrane.

13. Line 264-265: "… alanine mutations introduced into hFL abolished response to GAP14 while not affecting protein or plasma membrane localization (supp. Figure 6)". However, if you look at supplemental figure 6B, their mutant proteins express much less compared to wild type. In addition, it is not easy to compare membrane expression in figure supp 6C without some method of quantification, but the mutant expression again looks lower than WT. This means their data should be normalized to expression levels, and their new results may actually be different than they are showing in supp. 6A.

In particular T1240 is indeed expressed at lower levels than the other constructs (see added WB quantification) but expression level seems reasonable (see also ICC).

We have edited the text to dampen our conclusions as requested.

14. Line 336: Their expression levels are clearly different from supp. Figure 8. They have to normalize to expression levels.

We have quantified the Western Blot (Figure 4 supplement figure 4C) and added FLAG flow cytometry data showing the membrane levels of the constructs (Figure 4 supplement figure 4D,E). We edited the text accordingly, in case the 50% reduction in membrane expression would not be sufficient for generating the full activity levels.

15. Line 363: "all mutants expressed well": it is difficult to compare without some type of quantification.

We have added a Western Blot, with quantification, showing the total expression of the constructs to complement the immunocytochemistry data (Figure 5 – supplement figure 1B). Expression of the constructs can be considered as reasonable according to the pattern seen by immunocytochemistry and the least expressed mutants, 1077QDN to HDG1079, with the lowest expression level by Western Blot, still shows WT-like activity in the functional assay.

16. Line 364/365: It is a stretch to say that hCTFbaxG1011K "resembles mCTFbax". Please reword to something like " the EC50 of hCTFbaxG1011K is shifted towards mCTFbax".

We followed the suggestion and adapted the wording accordingly.

17. Figure 5: Data must be collected in three independent experiments, and it is not acceptable to not show data.

We have added data as recommended and the graph now represents a mean of n=3-5 independent experiments (Figure 5E).

18. Figure 6 and supplemental Figure 10: it is hard to evaluate their claims without quantification of their expression and normalizing their data to their expression.

We have included a Western Blot for increased clarity on the expression of the constructs (Figure 6 – supplement figure 1C). Quantification of the total expression levels shows that the two mutants hCTFbaxA1254T and hCTFbax V1258A are expressed at higher levels relative to the reference construct hCTFbax mBS, suggesting that expression levels are sufficient for highlighting potential activity.

19. Figure 6B: Data must be collected in three independent experiments. it is not clear how this data was collected. Does "repeat" mean independent experiments?

Per the suggestion, the graph in Figure 6B now represents an n=3 independent experiments with statistical analysis.

20. Figure 7 A and B: Data must be collected in three independent experiments.

We have added data to obtain n=3-4 replicates for these experiments with statistical analysis.

21. Discussion could be trimmed as well.

The Discussion section has been streamlined as suggested. And a paragraph now comments the latest aGPCR cryoEM structures.

Reviewer 2:

1. To address points 2, 5 and 6 in my public review, the authors should perform additional quantification of data and/or statistical comparisons.

We have addressed these points by adding quantification of expression, as permitted by the N-terminal or C-terminal epitope tag used in the constructs (Figure 3C; Figure 4C,D and E; Figure 4 supplement figure 3D; Figure 4 supplement figure 4C,D and E; Figure 5 supplement figure 1B; Figure 6 supplement figure 1C). For the concentration-response curves, we also added statistical analysis on the graphs, and all EC50 values are summarized in Figure 10.

2. To address points 1, 3, 4, and 7 in my public review, the authors should either add further data that supports their claims (if they want to maintain the interpretation of their data as currently written) or alternatively they should alter the discussion of their findings if some of their interpretations cannot be more strongly supported by additional data.

Please see the specific replies below in the Public Review section. We have edited the text as requested.

Reviewer 3:

1. Title is confusing when referring to "… in extracellular loop 2 of the transmembrane region" and should preferably indicate "… in extracellular loop 2 and the transmembrane region".

We have edited the title per the suggestion.

2. The authors should analyze the role of the highly conserved Histidine residue in position 991 by generating at least one other substitution mutant with a conservative amino acid. A phenotypic rescue strategy could then be conducted by overexpressing the conservative mutant on the GPR116 knock-out background (previously generated by the research team). A parallel in vitro validation of the receptor mutant in HEK293 cells can be achieved to compare activation by GAP peptides, constitutive activity, expression and cleavage parameters all of which would help reinforce the authors' hypothesis on whether it is a lack of cleavage rather than the substitution of a highly conserved residue that is causing the described phenotypes.

We carefully considered the reviewers suggestion and offer the following two arguments in response to their inquiry:

3. Authors should provide a more detailed characterization of the GPR116 H991A/H991A mouse line. First, tissue expression of the mutated receptor should be assessed to discard the probability of a loss-of-function phenotype due to a lack of expression. Second, a direct comparison of AT2 cells secretion parameters should be included for the different genotypes (GPR116+/+, GPR116 -/-, GPR116 H991A/H991A), in order to gain direct mechanistic insights into genotype-linked phenotypes and evaluate the degree of loss-of-function phenotypes between GRP116-deficient mice and cleavage-deficient mice. Third, phospholipid homeostasis parameters should be tested further using AT2 cells from these mice in presence and absence of ATP stimuli (phospholipid secretion, phospholipid uptake).

First, we have generated additional data demonstrating comparable expression levels of H991A mRNA in primary AT2 cells to that seen in WT AT2 cells (Figure 2 —figure supplement 1D). Since we chose not to epitope tag the H991A knock-in construct in the mouse and lack a reliable antibody against GPR116, we are unable to quantitate and localize H991A protein in the animal model. However, we observed similar calcium responses in response to peptide stimulation in primary AT2 cells isolated from H991A/H991A mice compared to those seen in WT AT2 (Figure 2C and D). Taken together, these data strongly suggest that expression levels and membrane localization of H991A in the knock-in are similar to the WT protein in littermate control animals.

Second, we have generated additional data demonstrating that levels of the primary surfactant phospholipid, saturated dipalmitoylphosphatidylcholine (SatPC), are increased in the alveolar lavage fluid of H991A/H991A homozygous mice at levels comparable to those seen in aged matched GPR116-/- mice (Figure 2A). We believe that these data, together with: (1) similar histological findings in H991A/H991A and GPR116-/- mice; (2) similar mRNA levels in H991A and WT primary AT2 cells; and (3) similar peptide-induced calcium responses in H991A/H991A primary AT2 cells demonstrate that the H991A receptor is responsive in vitro but inactive in vivo.

Third, the primary goal of generating the cleavage-deficient mutant was to determine if receptor activation in vivo was dependent on cleavage at the GPS. Based on the data presented, we believe we have successfully demonstrated that the H991A mutant is expressed on the cell surface, is activated by exogenous peptide in a transiently transfected cell line and in primary AT2 cells, but is not functional in vivo based on the identical pulmonary phenotype of the H991A homozygous mouse line compared to the germline knock-out mouse line. We respectfully disagree that a complete characterization of the surfactant phospholipid secretion and uptake parameters in the H991A mouse line would add additional insight into the biology of the GPR116 beyond what is already presented in the manuscript.

4. Authors should determine expression levels for each receptor constructs in order to normalize their functional data accordingly. N-terminally Flag-tagged constructs provide an excellent opportunity to evaluate membrane exposure of mCTF receptors from the cell surface of HEK293 cells. This can be achieved by using flow cytometry (as performed in Supp Figure 7 for quantifying N-terminal mCherry signal) quantifying cell-surface fluorescence intensity of cell populations expressing respective receptor mutants which can be detected with anti-Flag antibody and fluorophore-coupled secondary antibody. Alternatively, a cell ELISA can be conducted using the same strategy but revealing with horseradish peroxidase substrates. As for C-terminally V5-tagged constructs, they can be analyzed also by flow cytometry coupled to immunofluorescence in order to obtain total protein expression levels as the positioning of the tag does not allow to make a distinction between subcellular compartments. For western blotting experiments, although band intensities can be visually approximated from western blot images, we highly recommend that authors make use of pixel intensity-based quantification software to monitor band intensities normalized using housekeeping proteins as loading controls.

As suggested, we have now included appropriate quantification for each set of constructs as follows:

We also edited the text as requested.

5. P.11, the authors conducted activation assays rather than binding assays and thus should refrain from inferring that " … set out to determine the region of the receptor to which the tethered agonist binds…". This sentence should be rephrased in order to better reflect the correlation that the authors try to establish using their structure-function assays strategy. Additionally, every mention of a binding site determination throughout the manuscript should be nuanced with this aspect in mind.

We rephrased several parts of the Results and Discussion sections accordingly including taking into account data presented in Figure 8D that suggests the possibility of peptide binding into the putative binding site.

6. In their systematic characterization of critical residues by conservative substitutions the authors have dismissed the T1240 position which leaves this seemingly systematic approach incomplete. In order to show consistency, we recommend that they generate a Threonine to Serine replacement at this position and include the analysis in the manuscript.

We have generated this construct as requested and demonstrate that the T1240S mutant is less responsive to peptide stimulation as compared to the parent mCTFbax construct. These data represented in Figure 4G of the revised manuscript.

7. In the generation of basal activity-null constructs ("bax" constructs), it is not clear why a different engineering strategy was adopted to generate the human versus mouse version. The authors should at least allude to it in the manuscript by shortly explaining or indicating if technical or circumstantial elements played a role in designing these different versions, or if other versions of hCTFbax where in fact designed but did not result in reduction in constitutive activity.

We added a comment in the Methods section with regard to the two different strategies. The hCTFbax construct was based on published studies on other aGPCRs, hypothesizing that deleting 6 amino acids was an effective approach to abolish the basal activity of the hCTF construct. The mCTFbax construct was generated in our previously published work (Brown et al., 2017) and we thought it to be appropriate to test hypotheses in this study.

8. For consistency purposes, the authors should evaluate all mGPR116 full-length versions of receptor mutants modifying key ECL residues with a version of full-length mGPR116 also containing an intracellular V5 epitope tag to discard any collateral effects due to the insertion of a tag that could potentially disrupt intracellular coupling events. This is particularly important giving that the human versions containing an intracellular V5 epitope (hFL versions) display expression differences (Supp Figure 6B).

Experiments in Figure 4 E,F and Figure 4 supplement figure 3A have been replicated, using the V5-tagged version of the full length receptor as a control. This permitted more accurate comparison of the expression levels between the reference construct and the mutants thereof. Quantification of total expression levels by flow cytometry were also added to complement the immunocytochemistry data.

9. In order to allow for a more comprehensive reading, the authors should briefly explain in the text what their strategy was when using different GAP peptides interchangeably for the different assays.

We commented in the Methods section the rationale for using GAP14 as reference peptide. GAP9 is the peptide with the minimum number of amino acids required for receptor activation comparable to that seen with GAP16 (previously published). GAP10 is more active than GAP9 and was used for specific studies looking at the importance of selective GAP amino acids.

Ex vivo and related experiments were performed originally with the GAP16 peptide. In additional experiments, GAP10 was used as a more active peptide.

10. The manuscript would greatly benefit from the inclusion of a table reporting the EC50 values obtained for all calcium transient experiments as this would allow for a more accurate comparison between the different conditions.

We have added Figure 10 reporting all EC50s and statistical analyses of the experiments.

11. Methodology: Immunocytochemistry- Please describe the reagents and their concentrations used for fixation, permeabilization and blocking methods. Calcium transients- Please briefly specify M3R activation protocol.

We have enhanced the Methods sections to include all three of these aspects.

12. P.15, Please correct the sentence as it contains a repetitive portion: “Conservative exchanges for the three other critical amino acids still yielded inactive receptors… all yielded inactive receptors”

13. P16, please correct “… high probability of interactint…”.

14. P.18, please correct "… have been have been…".

15. P.20, please correct "… structural aspects aGPCRs activation, …".

Thank you for highlighting these errors – they have been corrected in the revision.

16. Figure 2 panels C and D, please include data obtained for control mice.

We have added additional data from wild-type control mice for the SatPC measurements (Figure 2A) and for calcium transient assays in primary AT2 cells (Figure 2C and D).

17. Figure 2: Please indicate data representation (mean), statistical error and analysis for panels C and D in figure legend

Added as requested.

18. For reproducibility purposes we recommend that the experimental set displayed in Figure 3 panel E for calcium and IP1 accumulation assays, be completed with at least n = 3 and after doing so, please indicate in figure legend the number of experimental repetitions, data/error type and statistical analysis conducted. Also, please indicate in the table the units used for IP1 accumulation assays as well as the respective concentration of indicated activating peptides that were used in this assay.

We have deleted the single IP1 data set and added calcium data to reach 3 independent experiments. Two peptides were however degraded in the meantime and could not be re-tested. We are presenting the data in a more concise way, including statistical analysis.

19. Figure 3 panel D, please indicate in figure legend the proper description of data representation (mean), error and statistical analysis as well as representativity (n of experiments). Also, please include in the panel the "dash line" which is mentioned in the figure legend.

We have edited the presentation of this figure and legend as suggested (Figure 3E)

20. Figure 3 panel B, please identify the mCTF lane as such.

Thank you for highlighting this error –mCTF was added to the figure as requested (Figure 3B).

21. Figure 8 panel A, please indicate which critical residues are represented by the other spheres at the top of TM3, middle and top of TM2, bottom of TM5, top of TM7 and/or TM2.

We have revised Figure 8 and improved the labelling of the new version.

22. Please provide scale bars for all microscopy images since some images appear to have been captured with a different zoom magnification (For example Supp. Figure 9).

We added the scale bars as suggested (Figure 4 supplement figure 1A, Figure 4 supplement figure 3AandC, Figure 5 supplement figure 1B, Figure 6 supplement figure 1B).

23. Figure legend for Supp Figure 6, please correct "HEK296" for "HEK293".

Thank you for highlighting this typo – it has been corrected in the revision (Figure 4 – supplement figure 3C).

24. Figure legend Supp. Figure 10, please indicate if results describe transient or stable HEK293 transfections.

This information was added for clarification (Figure 6 – supplement figure 1).

25. Supp. Figure 11, the table's second column title indicates "extracellular part of the NTF…" but should rather say "N-terminal part of the CTF…".

Thank you for this clarification. Text was edited as suggested (Figure 9).

26. Supp. Figure 11, please indicate with an asterisk the GPS cleavage-deficient aGPCR such as ADGRG5.

We added this information as suggested (Figure 9).

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

We are most intrigued by the work you have reported about the importance of autoproteolysis for the GPR116 function in vivo. Please address the additional issues that the reviewers raised below in their comments including:

– Please discuss the new GPR116 paper that describes a new ligand.

We added and discussed this reference in the context of our work in the Introduction section of our manuscript.

– Clarify the points about reproducibility.

We have added all the missing information and clarified the requested aspects. We also justified the single experiments for quantification of the receptor at protein level.

– Revise the title so the story can be better appreciated by the broad audience of eLife.

We have changed the title to: Regulation of pulmonary surfactant by the adhesion GPCR GPR116/ADGRF5 requires a tethered agonist-mediated activation mechanism.

– Rearrange the adhesion GPCR schematic in Figure 1 to correctly indicate the adhesion GPCR domains, including the GAIN domain and the GPS motif which is a peptide inside of the GAIN domain. Please also correct the same issue in the instruction.

We have modified the schematic in Figure 1 as requested and have edited the text referring to the schematic in the Introduction section.

– Provide a GPR116 TM/ peptide model based on the new adhesion GPCR structures. The current model is based on a class B family member.

We have generated a new model based on the cryo-EM structure of GPR110 and revised the results and Discussion sections accordingly.

Reviewer #2 (Recommendations for the authors):

The authors were very responsive to the reviewers' comments and addressed all of the reviewers' concerns. The textual changes and new data added by the authors have significantly strengthened the manuscript.

One additional comment I would like to make is that after the review of the original draft of this manuscript in Spring 2021, a paper was published reporting the secreted protein FNDC4 as a ligand for GPR116 (Georgiadi et al., Nat. Comm., 2021). This work is not mentioned in the present manuscript, and indeed the authors have a statement in the penultimate paragraph of their Introduction stating, "Still considered an orphan aGPCR, GPR116 has been proposed…"

Is GPR116 still an orphan? It is understood that FNDC4 cannot be considered a definitive ligand for GPR116 until other groups have had a chance to confirm (or refute) the findings of Georgiadi and colleagues, but nonetheless, it seems that the work of Georgiadi et al. is highly relevant to the studies described in the present manuscript and therefore should at least be mentioned at some point.

Along these same lines, it is terrific that the authors of the present manuscript made the effort to cite the recent wave of cryo-EM studies on aGPCRs and place their findings in the context of those new structural studies. In a similar vein, it would also be appropriate for the authors to cite the recently-published work of Georgiadi et al. and discuss how these findings may be relevant to the authors' own findings of the activation mechanism of GPR116.

Thank you for highlighting this point. We have included this FNDC4 reference in the introduction section of our manuscript. If GPR116 activation by FNCD4 is indeed confirmed by an independent group in the future, particularly in the context of pulmonary physiology, it could represent an interesting model to evaluate the dependence on the tethered peptide sequence for this agonist.

Reviewer #3 (Recommendations for the authors):

I am satisfied with the authors' response to my original comments, but I have some suggestions that would need to be addressed for ease of reading, accuracy, and reproducibility purposes regarding the newly added data in this revised version:

1. To avoid confusion, I would suggest adding "Cell surface expression (Mean fluorescence)" as the title for the Y axis of all graphs reporting results from surface exposed epitope in flow cytometry (Flag): Figure 3C, Figure 4 D, Figure 4 Supp figure 4D-E.

Thank you for the suggestion – we changed the titles accordingly as requested.

2. Likewise, I would suggest indicating "Total expression (mean fluorescence)" as the Y-axis title of all graphs reporting flow cytometry results from intracellular epitopes (V5/mCherry). Figure 4E, Figure 4 Supp Figure 4B.

Thank you for the suggestion – we changed the titles accordingly as requested.

3. Refrain from using the terms “membrane expression” when the methodology that has been used does not allow this determination exclusively since the immunocytochemistry protocol, as currently described in the methods section, involves a permeabilization step. This is the case in Figure 4 Supp figure 3A and 3C.

We reformulated these sentences as requested.

4. Please complete the newly added data with the corresponding information on reproducibility parameters (# of independent experiments, define error bars). Error bar descriptions and/or # of independent experiments are missing for various figures involving functional assays or for expression quantifications by western blot or flow cytometry (western blot quantifications do not display errors? Was it done just once? Justify if this is the case as stable cell lines can show decaying expression with time). These include: Figure 3F; Figure 3 Supp Figure 1 and 2; Figure 4; Figure 4 Supp Figure 1B,3B,3D, 4B-E; Figure 5A,B,E; Figure 5 Supp Figure 1B; Figure 6B-C; Figure 6 Supp Figure 1C; Figure 7; Figure 10 (error is SD or SEM?).

We added in all required figure legends the details on the presented data (average +/- SD; number of independent experiments and technical replicates). With respect to quantification of receptor expression by Western blot or flow cytometry: we performed these experiments in parallel to one of the functional experiments, to relate the two readouts. Two notable exceptions are Figure 4 Suppl Fig4D and Fig6 Suppl1C, which were run independently of functional assays; this flow cytometry experiment and western blot were therefore performed with freshly thawed vials of early passages, exactly for the reason mentioned by the reviewer.

5. It seems that flow cytometry experiments were performed only once, indicate if this is not the case.

Yes, these were single experiments. See above.

6. For flow cytometry experiments, indicate the number of events analyzed in the methods section.

We enhanced the methods section for flow cytometry with the number of cells measured for the various constructs.

7. The use of the term “biological replicates” seems incorrect throughout figure legends as they seem to indicate technical replicates instead. One experiment done at the same time is a n=1 that might include various replicates of each different groups, considered technical replicates; when the same experiment is done more than once at different times experiments are considered biological replicates. For example, the legend for Figure 4F indicates 3 independent experiments with 4 biological replicates but instead should read as 3 independent experiments done in quadruplicates or 4 technical replicates. Please revise where relevant and correct if this is the case or add if it is missing (For example Fig3F, Figure 3 Sup Figure 1, and others are missing replicates data).

We revised the figure legends accordingly.

8. Indicate where relevant when experiments are technical replicates instead of biological replicates. Add information about statistical significance where data represent biological replicates.

We revised the figure legends accordingly.

9. Because the data seems more relevant to the reader in this case, please interchange current panel E in Figure 4 with surface expression graphs for remaining mutants displayed in this figure depicted in Figure 4 Supp Figure 4 D-E.

We modified Figure 4 and related supplement Figure 4 as suggested.

10. Line 660, please correct the antibody incubation time indicating 230 min.

Done.

11. Indicate “% IP1 conversion” as the Y-axis title for all corresponding graphs.

Done (Figure 1D, Figure 3D, Figure3 Supplemental Figure 1A,B).

12. Note that no cell surface data expression is present for hFL-T1240A and is also missing for various hFL or hCTFbax or mCTF mutants. If data cannot be included at this stage, please include a brief comment in the manuscript to the effect of why this is the case in each section where the data is missing.

We have done our best to complement the Western blot data with immunocytochemistry to be transparent on the visible membrane localization of the receptor and associated mutants. We have now added a comment in each relevant section, when membrane quantification was not possible.

13. Figures 9 and 10 seem more suited for the supplementary section.

These data have been moved and are now referred to as Appendix-Table 1 and Appendix-Table 2.

Author details

1. James P Bridges

   Department of Pediatrics, Perinatal Institute, Section of Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States

   Present address

   Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, United States

   Contribution

   Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-4815-117X

2. Caterina Safina

   Novartis Institutes for Biomedical Research, Basel, Switzerland

   Contribution

   Resources, Investigation

   Competing interests

   is employed by and shareholder of Novartis Pharma AG

3. Bernard Pirard

   Novartis Institutes for Biomedical Research, Basel, Switzerland

   Contribution

   Conceptualization, Visualization, Methodology, Writing – review and editing

   Competing interests

   is employed by and shareholder of Novartis Pharma AG

4. Kari Brown

   Department of Pediatrics, Perinatal Institute, Section of Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States

   Present address

   Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, United States

   Contribution

   Resources, Investigation

   Competing interests

   No competing interests declared

5. Alyssa Filuta

   Department of Pediatrics, Perinatal Institute, Section of Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States

   Present address

   Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, United States

   Contribution

   Resources, Investigation

   Competing interests

   No competing interests declared

6. Ravichandran Panchanathan

   Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, United States

   Contribution

   Resources, Investigation

   Competing interests

   No competing interests declared

7. Rochdi Bouhelal

   Novartis Institutes for Biomedical Research, Basel, Switzerland

   Contribution

   Conceptualization, Resources, Investigation

   Competing interests

   is employed by and shareholder of Novartis Pharma AG

8. Nicole Reymann

   Novartis Institutes for Biomedical Research, Basel, Switzerland

   Contribution

   Investigation

   Competing interests

   is employed by and shareholders of Novartis Pharma AG

9. Sejal Patel

   Novartis Institutes for Biomedical Research, Cambridge, United States

   Contribution

   Conceptualization, Resources, Writing – review and editing

   Competing interests

   is employed by and shareholder of Novartis Pharma AG

10. Klaus Seuwen

    Novartis Institutes for Biomedical Research, Basel, Switzerland

    Contribution

    Conceptualization, Resources, Formal analysis, Validation, Investigation, Writing – review and editing

    Competing interests

    is employed by and shareholder of Novartis Pharma AG

11. William E Miller

    Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, United States

    Contribution

    Conceptualization, Resources, Formal analysis, Supervision, Validation, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing

    Competing interests

    No competing interests declared

12. Marie-Gabrielle Ludwig

    Novartis Institutes for Biomedical Research, Basel, Switzerland

    Contribution

    Conceptualization, Resources, Formal analysis, Supervision, Validation, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing

    For correspondence

    marie-gabrielle.ludwig@novartis.com

    Competing interests

    is employed by and shareholder of Novartis Pharma AG

    "This ORCID iD identifies the author of this article:" 0000-0002-7799-4782

• 615

  Page views

• 197

  Downloads

• 2

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.